ES2110738T3 - Inhibidores de farnesil:proteina transferasa como agentes anticancerosos. - Google Patents

Inhibidores de farnesil:proteina transferasa como agentes anticancerosos.

Info

Publication number
ES2110738T3
ES2110738T3 ES94909497T ES94909497T ES2110738T3 ES 2110738 T3 ES2110738 T3 ES 2110738T3 ES 94909497 T ES94909497 T ES 94909497T ES 94909497 T ES94909497 T ES 94909497T ES 2110738 T3 ES2110738 T3 ES 2110738T3
Authority
ES
Spain
Prior art keywords
farnesil
inhibitors
cancer agents
protein transferase
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94909497T
Other languages
English (en)
Inventor
David M Stemerick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2110738T3 publication Critical patent/ES2110738T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4015—Esters of acyclic unsaturated acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3821—Acyclic saturated acids which can have further substituents on alkyl substituted by B, Si, P or a metal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826—Acyclic unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C07F9/4012—Esters of acyclic acids which can have further substituents on alkyl substituted by B, Si, P or a metal

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A CIERTOS INHIBIDORES DE TRANSFERASA FARNESIL:PROTEINA QUE SON UTILES COMO AGENTES ANTINEOPLASTICOS.
ES94909497T 1993-02-23 1994-01-24 Inhibidores de farnesil:proteina transferasa como agentes anticancerosos. Expired - Lifetime ES2110738T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2141193A 1993-02-23 1993-02-23

Publications (1)

Publication Number Publication Date
ES2110738T3 true ES2110738T3 (es) 1998-02-16

Family

ID=21804071

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94909497T Expired - Lifetime ES2110738T3 (es) 1993-02-23 1994-01-24 Inhibidores de farnesil:proteina transferasa como agentes anticancerosos.

Country Status (19)

Country Link
US (1) US5463181A (es)
EP (1) EP0686159B1 (es)
JP (1) JPH08509470A (es)
KR (1) KR100305128B1 (es)
CN (1) CN1045207C (es)
AT (1) ATE159023T1 (es)
AU (1) AU684071B2 (es)
CA (1) CA2154871C (es)
DE (1) DE69406110T2 (es)
DK (1) DK0686159T3 (es)
ES (1) ES2110738T3 (es)
FI (1) FI111369B (es)
GR (1) GR3025499T3 (es)
HU (1) HUT72647A (es)
IL (1) IL108694A0 (es)
NO (1) NO306618B1 (es)
NZ (1) NZ262585A (es)
TW (1) TW265345B (es)
ZA (1) ZA941099B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
FR2833266B1 (fr) * 2001-12-11 2004-10-22 Mayoly Spindler Lab Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
EP2671507A3 (en) 2005-04-28 2014-02-19 Proteus Digital Health, Inc. Pharma-informatics system
MX2009002893A (es) 2006-09-18 2009-07-10 Raptor Pharmaceutical Inc Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
CA2752373C (en) 2009-02-20 2017-10-10 To-Bbb Holding B.V. Glutathione-based drug delivery system
IL255113B (en) 2009-05-06 2022-09-01 Laboratory Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57142993A (en) * 1981-02-28 1982-09-03 Sagami Chem Res Center 2-hydroxyphosphonic diester
DE3313070A1 (de) * 1983-04-12 1984-10-18 Bayer Ag, 5090 Leverkusen Chlorierte phosphorylmethylcarbonyl-derivate, verfahren zu ihrer herstellung und ihre verwendung in pflanzenschutmitteln
DE3425701A1 (de) * 1984-07-12 1986-01-16 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von chlorierten phosphorylmethylcarbonyl-derivaten und neue zwischenprodukte zu ihrer herstellung
US4924024A (en) * 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
US5177239A (en) * 1989-07-18 1993-01-05 E. R. Squibb & Sons, Inc. Method for preparing a phosphonic acid ester
US5298655A (en) * 1991-09-27 1994-03-29 Merck & Co., Inc. Farnesyl pyrophosphate analogs

Also Published As

Publication number Publication date
DK0686159T3 (da) 1998-01-26
DE69406110T2 (de) 1998-05-14
NO306618B1 (no) 1999-11-29
EP0686159A1 (en) 1995-12-13
NZ262585A (en) 1997-12-19
FI953934L (fi) 1995-08-22
FI953934A0 (fi) 1995-08-22
CN1118166A (zh) 1996-03-06
JPH08509470A (ja) 1996-10-08
EP0686159B1 (en) 1997-10-08
CA2154871A1 (en) 1994-09-01
ZA941099B (en) 1994-08-30
DE69406110D1 (de) 1997-11-13
KR100305128B1 (ko) 2001-11-22
ATE159023T1 (de) 1997-10-15
TW265345B (es) 1995-12-11
FI111369B (fi) 2003-07-15
IL108694A0 (en) 1994-05-30
AU6232494A (en) 1994-09-14
AU684071B2 (en) 1997-12-04
NO953292D0 (no) 1995-08-22
NO953292L (no) 1995-08-22
GR3025499T3 (en) 1998-02-27
US5463181A (en) 1995-10-31
HUT72647A (en) 1996-05-28
HU9502455D0 (en) 1995-10-30
CN1045207C (zh) 1999-09-22
CA2154871C (en) 1998-04-07

Similar Documents

Publication Publication Date Title
HN1998000168A (es) Derivados de la tienapirimidina y de la tienapiridina utiles como agentes anticancerigenos.
HN1994000083A (es) Aparato de cierre
HN1997000118A (es) 1,3, oxa thiolane nucleoside compuestos y composiciones
HN1998000011A (es) Derivados de acidos arilsulfonilaminohidroxamicos
HN1997000126A (es) Derivados de indazol
HN1998000177A (es) Compuestos azopoliciclicos condensados con arilo
HN1998000036A (es) Compuesto de pirazina
ES2138622T3 (es) Derivados de mercaptoacetilamido piridazo(1,2-a)(1,2)diazepina utilizados como inhibidores de encefalinasa y eca.
HN1996000082A (es) Compuestos de quinolina y quinozssolina utiles en terapia.
HN1998000139A (es) Pirimidin-4-ona y pirimidin-4-tiona novedosas como funguicidas
HN1999000089A (es) Formulaciones de ziprasidona
HN1998000124A (es) Terapia de combinacion
ES2114870T3 (es) Nuevos derivados de mercaptoacetilamida utiles como inhibidores de encefalinasa y eca.
HN1999000066A (es) Formulaciones farmaceuticas
HN1997000097A (es) Piridinas condensadas con heterociclicos
HN1998000118A (es) 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
AR003466A1 (es) Compuestos 14-hidroxi-2-desoxoparahercuamida b
HN1997000146A (es) Derivados de pirimidina biciclica condensada
HN1999000125A (es) Nuevos derivados sustituidos del pirazol
ES2098140T3 (es) Liosferas que contienen gonadotropina.
HN1998000030A (es) 2-amino-6-(4fenoxi-2-sustituido)-piridinas sustituidas
HN1998000115A (es) Formas de dosificación farmacéuticas sólidas
DK0515544T3 (da) Steroidsulfataseinhibitorer
HN1998000002A (es) Compuestos de quinolina y de quinazolina utiles en terapia
HN1998000088A (es) Tratamiento de resistencia a la insulina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 686159

Country of ref document: ES